Browsing ICR Divisions by author "Turajlic, Samra"
Now showing items 1-9 of 9
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study.
Au, L; Fendler, A; Boos, LA; Byrnes, F; Shepherd, S; et al. (AMER ASSOC CANCER RESEARCH, 2020-03-01) -
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.
Powell, N; Ibraheim, H; Raine, T; Speight, RA; Papa, S; et al. (ELSEVIER INC, 2020-07-01)Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated ... -
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.
Switzer, B; Haanen, J; Lorigan, PC; Puzanov, I; Turajlic, SThe clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review ... -
Escape from nonsense-mediated decay associates with anti-tumor immunogenicity.
Litchfield, K; Reading, JL; Lim, EL; Xu, H; Liu, P; et al. (NATURE PUBLISHING GROUP, 2020-07-30)Frameshift insertion/deletions (fs-indels) are an infrequent but highly immunogenic mutation subtype. Although fs-indels are degraded through the nonsense-mediated decay (NMD) pathway, we hypothesise that some fs-indels ... -
Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.
Flynn, M; Pickering, L; Larkin, J; Turajlic, S (2018-01)Immune-checkpoint inhibitors (ICPIs), including antibodies against cytotoxic T-lymphocyte associated antigen 4 and programmed cell death protein 1, have been shown to induce durable complete responses in a proportion of ... -
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui, MS; Lai, ZM; Spain, L; Greener, V; Turajlic, S; et al. (SPRINGER, 2020-05-24)PURPOSE: Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including ... -
SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay
Buck, MD; Poirier, EZ; Cardoso, A; Frederico, B; Canton, J; et al. (F1000 Research Ltd, 2021-01-21)The ongoing pandemic of SARS-CoV-2 calls for rapid and cost-effective methods to accurately identify infected individuals. The vast majority of patient samples is assessed for viral RNA presence by RT-qPCR. Our biomedical ... -
Systemic treatment of advanced papillary renal cell carcinoma: Where next?
Turajlic, S; Larkin, J (2016-12)